Results 51 to 60 of about 16,704,778 (257)
Case Reports in Gastrointestinal Medicine, 2021 Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo +15 more
doaj +1 more source
Hemostasis disorders in patients with systemic AL-amyloidosis
Терапевтический архив, 2023 Aim. To analyze the frequency and nature of hemorrhagic and thrombotic complications in patients with systemic AL-amyloidosis and compare with laboratory changes in the hemostasis system. Materials and methods.
Irina G. Rekhtina +4 more
doaj +1 more source
Light chain systemic amyloidosis manifested as liver failure complicated with fatal spontaneous splenic rupture: A case report [PDF]
arXiv, 2021 For a patient with manifestations of nausea, abdominal distension, spontaneous splenic rupture, obvious liver enlargement, low red blood cells and platelets, yellow sclera, and spider angioma, Congo red staining of liver and spleen tissues indicated amyloidosis.
arxiv
Nanobody interaction unveils structure, dynamics and proteotoxicity of the Finnish-type amyloidogenic gelsolin variant [PDF]
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.
Volume 1865, Issue 3, 1 March 2019, Pages 648-660, 2019 AGel amyloidosis, formerly known as familial amyloidosis of the Finnish-type, is caused by pathological aggregation of proteolytic fragments of plasma gelsolin. So far, four mutations in the gelsolin gene have been reported as responsible for the disease.
arxiv +1 more source
Blood, 2020 Daratumumab, a monoclonal CD 38 antibody, is approved in the treatment of myeloma, but its efficacy and safety in AL amyloidosis has not been formally studied.
V. Sanchorawala +8 more
semanticscholar +1 more source
Incidence and clinical outcome of renal amyloidosis: A retrospective study
Saudi Journal of Kidney Diseases and Transplantation, 2013 The kidneys are affected in almost all patients with amyloid A in secondary amyloidosis (AA) amyloidosis but less frequently in immunoglobulin light chains in primary systemic amyloidosis (AL) amyloidosis.
Emad Abdallah, Emam Waked
doaj +1 more source
Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
Frontiers in Immunology, 2022 BackgroundEmerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light ...
Jipeng Yan +15 more
doaj +1 more source
A case of amyloid light amyloidosis involving multiorgan with hepatomegaly as the main manifestation [PDF]
Yixue xinzhi zazhi, 2023 Amyloid light (AL) amyloidosis, also known as primary systemic amyloidosis, is a protein conformation disease, and is a clinical syndrome of functional failure of affected organs due to abnormal folding and deposition of insoluble fibrin in the ...
Ya-Nan CHEN +5 more
doaj +1 more source
Korean Journal of Transplantation, 2020 Amyloid light-chain (AL) amyloidosis after kidney transplantation is a rare disease in the world, and only one case of systemic AL amyloidosis after kidney transplantation is reported in Korea.
Sung Hyun Park +8 more
doaj +1 more source
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Therapeutic Advances in Hematology, 2021 Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface.
Foteini Theodorakakou +2 more
doaj +1 more source